Non invasive approaches to the earlier detection of disease

We have an active clinical diagnostics pipeline across oncology and inflammatory diseases.

Our large scale clinical trials

Our ambition is to save 100,000 lives and save healthcare providers $1.5 billion in costs. Owlstone, together with its clinical partners, are actively engaged in clinical research across cancer, inflammation and infectious diseases. We are running three large scale clinical trials and have a strategic relationship with the CRUK funded Cambridge Cancer Institute to develop biomarkers for the early detection of cancer.

LuCID - the early detection of lung cancer

Lung cancer is the most common cancer in the world with an estimated 1.8 million new cases and 1.6 million deaths each year. LuCID is a breath test for the early detection of lung cancer, currently undergoing clinical trials in up to 3,000 patients in 20 hospitals across Europe.

Learn more about LuCID

STRATA - stratifying asthma treatment

Asthma is the most common chronic airway disease in the world. We are working with clinical partners to develop breath based biomarkers that move asthma treatment from trial and error to matching the right patient to the right treatment.

Learn more about Strata

InTERCEPT - the early detection of colorectal cancer

Owlstone’s urine based test for the early detection of colorectal cancer has the potential to save up to 75,000 lives per year in the EU alone. Our 1,000 patient trial in collaboration with Warwick University is paving the way for earlier diagnosis. 

Learn more about Intercept

More information about our clinical pipeline

If you want to know more about our clinical pipeline: protocols, publications and other research materials are available from our Resources section by using the keyword based search function.

VOC biomarker discovery and validation research services with our world class team and facilities

View our services